← Petco Health & Wellness Company, Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|---|---|
| Net income (loss) | ($104.0m) | ($31.7m) | $159.8m | $89.9m | ($1.3b) | ($101.8m) | $9.1m | |
| Depreciation and amortization | $173.5m | $174.8m | $172.4m | $193.8m | $200.8m | $199.7m | $196.7m | |
| Amortization of debt discounts and issuance costs | $23.5m | $24.2m | $5.8m | $4.9m | $5.0m | $4.9m | $5.0m | |
| Provision for deferred taxes | ($45.1m) | $25.5m | $37.7m | ($893k) | ($53.5m) | ($30.5m) | $17.1m | |
| Impairments, write-offs and losses on sale of fixed and other assets | $11.9m | $15.6m | $10.9m | $2.0m | $2.8m | $8.8m | — | |
| Goodwill impairment | — | — | $0 | $0 | $1.2b | — | $0 | |
| Loss on partial extinguishment of debt | — | $17.5m | $20.8m | — | $920k | — | $565k | |
| Income from equity method investees | ($2.4m) | ($6.5m) | ($10.9m) | ($13.0m) | ($16.2m) | ($18.7m) | ($20.4m) | |
| Non-cash operating lease costs | $442.0m | $430.4m | $422.5m | $422.8m | $429.1m | $414.4m | $411.8m | |
| Operating lease liabilities | ($408.6m) | ($399.6m) | ($418.2m) | ($386.3m) | ($447.0m) | ($418.2m) | ($371.1m) | |
| Equity-based compensation expense | $9.5m | $12.9m | $49.3m | $60.8m | $81.9m | $50.2m | $32.6m | |
| Amounts reclassified out of accumulated other comprehensive loss (Note 8) | — | — | — | $168k | ($488k) | ($3.1m) | ($556k) | |
| Other non-operating income | — | — | ($34.5m) | $12.7m | ($4.7m) | ($4.8m) | $0 | |
| Receivables | ($3.8m) | ($10.3m) | ($13.8m) | $6.0m | $5.2m | $4.2m | ($5.6m) | |
| Merchandise inventories | ($8.2m) | ($60.6m) | ($136.4m) | $22.7m | ($32.1m) | $30.8m | $63.1m | |
| Prepaid expenses and other assets | ($5.2m) | ($13.8m) | ($17.7m) | ($5.9m) | ($8.0m) | ($4.0m) | $818k | |
| Accounts payable and book overdrafts | $15.9m | $46.3m | $71.8m | ($22.8m) | $103.9m | $8.5m | ($43.0m) | |
| Accrued salaries and employee benefits | ($1.4m) | $34.3m | $10.7m | ($51.4m) | $11.3m | $57.0m | ($3.3m) | |
| Accrued expenses and other liabilities | ($3.0m) | ($28.3m) | $42.9m | $13.6m | ($8.5m) | ($12.5m) | $25.0m | |
| Other long-term liabilities | ($6.8m) | $27.4m | ($14.9m) | ($3.2m) | $3.0m | ($7.2m) | ($3.8m) | |
| Cash paid for fixed assets | ($156.9m) | ($159.6m) | ($239.1m) | ($278.0m) | ($225.6m) | ($128.0m) | ($127.1m) | |
| Cash paid for acquisitions, net of cash acquired (Note 3) | ($2.8m) | — | ($4.3m) | ($9.6m) | ($6.7m) | ($629k) | — | |
| Cash paid for investment | — | — | — | — | — | ($457k) | — | |
| Proceeds from investments | — | $73k | $6.1m | — | $24.9m | $998k | — | |
| Proceeds from sale of assets | — | $3.3m | $226k | $2.3m | — | $1.4m | $2.5m | |
| Cash received from partial surrender of officers' life insurance | $1.5m | — | — | — | — | $2.8m | — | |
| Borrowings under long-term debt agreements | $1.3b | $476.0m | $1.7b | $123.0m | $273.0m | $201.0m | — | |
| Debt refinancing costs | ($58k) | — | ($24.7m) | — | — | ($3.0m) | — | |
| Payments for finance lease liabilities | ($3.4m) | ($3.4m) | ($3.6m) | ($5.1m) | ($5.9m) | ($5.7m) | ($5.6m) | |
| Proceeds from employee stock purchase plan and stock option exercises | — | — | $4.2m | $3.8m | $4.2m | $3.8m | $3.7m | |
| Tax withholdings on stock-based awards | — | — | ($33k) | ($15.6m) | ($8.7m) | ($6.3m) | ($4.6m) | |
| Capitalized interest | $953k | $499k | $1.0m | $1.5m | $1.3m | $729k | $844k | |
| Accounts payable and accrued expenses for capital expenditures | $22.0m | $19.7m | $36.9m | $29.1m | $18.9m | $13.0m | $15.7m | |
| Accrued tax withholdings on stock-based awards | — | — | $6.6m | — | $809k | — | — | |
| Net cash provided by operating activities | $110.3m | $268.6m | $358.2m | $346.0m | $215.7m | $177.7m | $314.1m | |
| Net cash used in investing activities | ($139.0m) | ($157.2m) | ($237.1m) | ($320.3m) | ($207.4m) | ($123.9m) | ($124.6m) | |
| Repayments of long-term debt | ($1.3b) | ($1.6b) | ($1.7b) | ($140.0m) | ($348.0m) | ($201.0m) | ($95.2m) | |
| Proceeds from issuance of common stock | — | — | — | — | — | $2.5m | — | |
| Net cash used in financing activities | ($3.1m) | ($146.6m) | ($18.8m) | ($33.8m) | ($85.4m) | ($8.8m) | ($101.7m) | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | ($31.8m) | ($35.2m) | $102.3m | ($8.2m) | ($77.1m) | $45.0m | $87.7m | |
| Cash, cash equivalents and restricted cash at beginning of year | $154.7m | $119.5m | $221.9m | $213.7m | $136.6m | $181.7m | $269.4m | |
| Cash paid for interest in veterinary joint venture (Note 1) | $217.7m | $179.0m | $64.5m | ($35.0m) | $142.1m | $138.6m | $124.7m | |
| Interest paid, net | $217.7m | $179.0m | $64.5m | $89.3m | $142.1m | $138.6m | $124.7m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.